Compare Cigna Corp (CI) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Hims and Hers Health Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Hims and Hers Health Inc trades at $30.53 (market cap $7.35B). The key difference: Cigna Corp is far larger — about 10× Hims and Hers Health Inc's market cap, and Cigna Corp pays a 2.24% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals.
| CI | HIMS | |
|---|---|---|
Market Cap | $73.56B | $7.35B |
Sector | Health | Health |
52-Week High | $311.00 | $62.76 |
52-Week Low | $244.41 | $14.52 |
Enterprise Value | $98.27B | $7.73B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
Hims & Hers Health stock trades at $31.59, up 6.51% today, showing strong momentum. The technical outlook is bullish, with the price above key moving averages and support at $30. Fundamentally, revenue growth is robust at 40% year-over-year in Q2 2026 (MarketBeat, 2026-08-10), but profitability remains challenged with a net loss margin of -0.56% in 2026. The company raised its annual revenue forecast to $3.1–3.3 billion (WSJ, 2026-08-10), reflecting confidence in subscriber growth and expansion into weight-loss treatments.
The investment outlook is mixed: strong revenue growth and bullish analyst targets near $35.60 offer upside, but high valuation ratios (P/E of 57.14) and recent earnings misses heighten risk. Key risks include margin pressure from GLP-1 investments and ongoing legal investigations. Wall Street sentiment is cautious, with 65% hold ratings, suggesting patience for profitability improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
